KR20200090143A - 마이셀리오프쏘라 써모필라에서 독감 백신의 생산 - Google Patents

마이셀리오프쏘라 써모필라에서 독감 백신의 생산 Download PDF

Info

Publication number
KR20200090143A
KR20200090143A KR1020207004901A KR20207004901A KR20200090143A KR 20200090143 A KR20200090143 A KR 20200090143A KR 1020207004901 A KR1020207004901 A KR 1020207004901A KR 20207004901 A KR20207004901 A KR 20207004901A KR 20200090143 A KR20200090143 A KR 20200090143A
Authority
KR
South Korea
Prior art keywords
ser
gly
leu
thr
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020207004901A
Other languages
English (en)
Korean (ko)
Inventor
마크 에말파브
튀니우스 코넬리스 페르부르트
마크 알. 알페니토
마크 베어
이자벨 레가스텔루와
마리-피에르 카제크
마리-클로틸드 버나드
장 듀베일
리차드 켄싱어
Original Assignee
다이아딕 인터내셔널 (유에스에이), 인크.
다이아딕 인터내셔널 (유에스에이), 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 다이아딕 인터내셔널 (유에스에이), 인크., 다이아딕 인터내셔널 (유에스에이), 인크. filed Critical 다이아딕 인터내셔널 (유에스에이), 인크.
Publication of KR20200090143A publication Critical patent/KR20200090143A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C12N1/145—Fungal isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16251—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/645—Fungi ; Processes using fungi

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Botany (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020207004901A 2017-08-21 2018-08-09 마이셀리오프쏘라 써모필라에서 독감 백신의 생산 Ceased KR20200090143A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762547885P 2017-08-21 2017-08-21
US62/547,885 2017-08-21
PCT/IB2018/056003 WO2019038623A1 (en) 2017-08-21 2018-08-09 PRODUCTION OF AN INFLUENZA VACCINE IN MYCELIOPHTHORA THERMOPHILA

Publications (1)

Publication Number Publication Date
KR20200090143A true KR20200090143A (ko) 2020-07-28

Family

ID=65438455

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207004901A Ceased KR20200090143A (ko) 2017-08-21 2018-08-09 마이셀리오프쏘라 써모필라에서 독감 백신의 생산

Country Status (9)

Country Link
US (2) US11738080B2 (enExample)
EP (1) EP3672630A4 (enExample)
JP (1) JP2020533966A (enExample)
KR (1) KR20200090143A (enExample)
CN (1) CN111315408A (enExample)
AU (1) AU2018319501A1 (enExample)
CA (1) CA3073646A1 (enExample)
IL (1) IL272568A (enExample)
WO (1) WO2019038623A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021229483A1 (en) * 2020-05-14 2021-11-18 Dyadic International (Usa), Inc. Modified filamentous fungi for production of exogenous proteins
CN117377752A (zh) * 2021-03-11 2024-01-09 二进国际(美国)有限公司 用于生产具有减少的或不含n-连接的糖基化的外源蛋白的遗传修饰的丝状真菌
WO2023225646A1 (en) 2022-05-20 2023-11-23 Phibro Animal Health Corporation Using fungal constructs to produce viral protein antigens

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3621995B2 (ja) 1994-05-20 2005-02-23 マウント シナイ スクール オブ メディシン オブ ニューヨーク ユニバーシティー 赤血球凝集素のアシル化／パルミチル化を抑制する抗ウイルス剤を用いるインフルエンザウイルス感染の治療
AU771539C (en) * 1998-10-06 2005-01-13 Dyadic International (Usa), Inc. Transformation system in the field of filamentous fungal hosts
HUP0300469A2 (hu) 2000-04-13 2003-06-28 Emalfarb, Mark Aaron Új, expressziós szabályzó szekvenciák és expressziós termékek fonalas gombákban
US8506967B2 (en) * 2003-07-11 2013-08-13 Novavax, Inc. Functional influenza virus like particles (VLPs)
EP1799261B1 (en) * 2004-10-15 2012-12-05 Intrexon Corporation Methods and compositions for combinatoral-based production of multivalent recombinant antigens
US8680252B2 (en) * 2006-12-10 2014-03-25 Dyadic International (Usa), Inc. Expression and high-throughput screening of complex expressed DNA libraries in filamentous fungi
WO2008073490A1 (en) * 2006-12-12 2008-06-19 Carrington Laboratories Inc., Purification of influenza viral antigens
CA2755417C (en) 2009-03-16 2018-11-13 Dyadic Nederland B.V. New fungal production system
EP2413962A1 (en) 2009-03-30 2012-02-08 Mount Sinai School of Medicine Influenza virus vaccines and uses thereof
WO2010150982A2 (ko) 2009-06-23 2010-12-29 한밭대학교 산학협력단 안전성이 뛰어난 인플루엔자 바이러스 백신용 재조합 헤마글루티닌 단백질 및 이를 함유하는 생분해성 ｐｌｇａ 미립자의 제조 방법
CN102985107A (zh) 2010-01-24 2013-03-20 生物模仿公司 免疫性流感成分
BR112014022506A2 (pt) * 2012-03-12 2018-11-06 Codexis Inc variantes de cbh1a
US20130315955A1 (en) 2012-04-13 2013-11-28 Protein Sciences Corporation Stability and potency of hemagglutinin
US10118951B2 (en) 2014-12-19 2018-11-06 Sanofi Pasteur Multimerization of recombinant protein by fusion to a sequence from lamprey
EP3384002A1 (en) 2015-12-02 2018-10-10 Basf Se Method of producing proteins in filamentous fungi with decreased clr2 activity

Also Published As

Publication number Publication date
WO2019038623A1 (en) 2019-02-28
US11738080B2 (en) 2023-08-29
EP3672630A4 (en) 2021-06-02
US20200215183A1 (en) 2020-07-09
JP2020533966A (ja) 2020-11-26
US20230346913A1 (en) 2023-11-02
EP3672630A1 (en) 2020-07-01
CA3073646A1 (en) 2019-02-28
CN111315408A (zh) 2020-06-19
AU2018319501A1 (en) 2020-04-02
IL272568A (en) 2020-03-31

Similar Documents

Publication Publication Date Title
AU2020200303B9 (en) Novel multivalent nanoparticle-based vaccines
KR101541330B1 (ko) 식물에서 생산된 헤마글루티닌을 포함하는 인플루엔자 바이러스-유사 입자(ＶＬＰｓ)
KR101956910B1 (ko) 헤마글루티닌을 발현하는 트랜스제닉 식물에서 생산된 재조합 인플루엔자 바이러스-유사 입자(ＶＬＰｓ)
KR101153929B1 (ko) 기능성 인플루엔자 바이러스 유사입자
DK2610345T3 (en) RECOMBINANT INFLUENZA VIRUS SIMULAR PARTICULARS (VLPS) MADE IN TRANSGENE PLANTS THAT EXPRESS HEMAGGLUTININ
US20230346913A1 (en) Production of flu vaccine in myceliophthora thermophila
CN102165062B (zh) 新的流感病毒免疫表位
US9795666B2 (en) High-yield transgenic mammalian expression system for generating virus-like particles
KR102199018B1 (ko) 식물에서 인플루엔자 바이러스-유사 입자 생산
CN101325966A (zh) 功能性流感病毒样颗粒(vlp)
CN110981968B (zh) 含有狂犬病病毒g蛋白的融合蛋白及其制备方法、应用和疫苗
EP3160501B1 (en) Influenza virus hemagglutinin protein as a vaccine antigen
TW200530402A (en) Recombinant baculovirus and virus-like particle
CN110272473A (zh) 甲型流感通用型病毒样颗粒及其制备方法和应用
CN111154778B (zh) 禽新城疫病毒新型基因工程亚单位疫苗
CN106905434B (zh) 一种包含蹄蝠肝炎病毒核心蛋白的重组融合蛋白及其制备方法和应用
CN106986943B (zh) 一种包含北极地松鼠肝炎病毒核心蛋白的重组融合蛋白及其制备方法和应用
CN113061167B (zh) 兔出血症病毒重组抗原及其应用
TW201139668A (en) Method for producing recombinant virus
CN116589596A (zh) 甲型流感na多肽广谱免疫原及其序贯免疫方法
HK40039523A (en) Influenza virus-like particle production in plants
CN119613561A (zh) 一种trpv1纳米圆盘蛋白及其制备方法和应用
AU2015202195A1 (en) New influenza virus immunizing epitope
KR19990022028A (ko) 인플루엔자 헤마글루티닌 다가 백신의 제조방법

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200219

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210802

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230817

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20231123

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20230817

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I